Review: An update on inflammatory and autoimmune myopathies

Neuropathology and Applied Neurobiology

Volumn 37, Issue 3, 2011, Pages 226-242

  Dalakas, M C ^a,b  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

^b THOMAS JEFFERSON UNIVERSITY   (United States)

Author keywords

Dermatomyositis; Inclusion body myositis; Muscle immunopathology; Necrotizing myositis; Polymyositis

Indexed keywords

ALEMTUZUMAB; AMYLOID; AMYLOID BETA PROTEIN; CD8 ANTIGEN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IMMUNOGLOBULIN; INTERLEUKIN 1BETA; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; RAPAMYCIN; RITUXIMAB;

ALZHEIMER DISEASE; AUTOIMMUNITY; CD8+ T LYMPHOCYTE; CELL STRESS; CELL VACUOLE; CYTOTOXIC T LYMPHOCYTE; DERMATOMYOSITIS; DIAGNOSTIC ERROR; HISTOPATHOLOGY; HUMAN; IMMUNOCOMPETENT CELL; IMMUNOPATHOLOGY; INCLUSION BODY MYOSITIS; INFLAMMATION; INFLAMMATORY CELL; MICROANGIOPATHY; MUSCLE BIOPSY; MUSCLE DISEASE; MYOPATHY; NECROTIZING AUTOIMMUNE MYOPATHY; NEOPLASM; NONHUMAN; PATHOGENESIS; PATHOLOGY; POLYMYOSITIS; PRIORITY JOURNAL; REVIEW; T LYMPHOCYTE; VIRUS INFECTION;

AUTOIMMUNE DISEASES; DERMATOMYOSITIS; HUMANS; MYOSITIS, INCLUSION BODY; POLYMYOSITIS;

EID: 79951801084     PISSN: 03051846     EISSN: 13652990     Source Type: Journal    
DOI: 10.1111/j.1365-2990.2010.01153.x     Document Type: Review

References (130)

1. Dalakas MC. Polymyositis, dermatomyositis, and inclusion-body myositis. N Engl J Med 1991; 325: 1487-98
2. Dalakas MC, Hohlfeld R. Polymyositis and dermatomyositis. Lancet 2003; 362: 971-82
3. Engel AG, Hohlfeld R, Banker BQ. The polymyositis and dermatomyositis syndrome. In Myology. Eds AG Engel, C Franzini-Armstrong New York: McGraw-Hill, 2006; 1335-83
4. Dalakas MC, Karpati G. The inflammatory myopathies. In Disorders of Voluntary Muscle 8th edn. Eds G Karpati, D Hilton-Jones, K Bushby, RC Griggs Cambridge: Cambridge University Press, 2010; 427-52
5. Dalakas MC. Polymyositis, dermatomyositis and inclusion body myositis. Harrison's Principles of Internal Medicine 17th edn. Eds AS Fauci, E Braunwald, DL Kasper, SL Hauser, DL Longo, JL Jameson, J Loscalzo New York, NY: McGraw-Hill, 2008; 2696-703
6. Mastaglia FL, Phillips BA. Idiopathic inflammatory myopathies: epidemiology, classification and diagnostic criteria. Rheum Dis Clin North Am 2002; 28: 723-41
7. Dalakas MC. Inflammatory muscle diseases: a critical review on pathogenesis and therapies. Curr Opin Pharmacol 2010; 10: 346-52
8. Schmidt J, Dalakas MC. Pathomechanisms of inflammatory myopathies: recent advances and implications for diagnosis and therapies. Expert Opin Med Diagn 2010; 4: 241-50
9. Dalakas MC. Sporadic inclusion body myositis - diagnosis, pathogenesis and therapeutic strategies. Nat Clin Pract Neurol 2006; 2: 437-47
10. Sekul EA, Dalakas MC. Inclusion body myositis: new concepts. Semin Neurol 1993; 13: 256-63
11. Needham M, Mastaglia FL. Inclusion body myositis: current pathogenetic concepts and diagnostic and therapeutic approaches. Lancet Neurol 2007; 6: 620-31
12. Koffman BM, Sivakumar K, Simonis T, Stroncek D, Dalakas MC. HLA allele distribution distinguishes sporadic inclusion body myositis from hereditary inclusion body myopathies. J Neuroimmunol 1988; 84: 139-42
13. Badrising UA, Schreuder GM, Giphart MJ, Geleijns K, Verschuuren JJ, Wintzen AR, Maat-Schieman ML, van Doorn P, van Engelen BG, Faber CG, Hoogendijk JE, de Jager AE, Koehler PJ, de Visser M, van Duinen SG. Dutch IBM Study Group. Associations with autoimmune disorders and HLA class I and II antigens in inclusion body myositis. Neurology 2004; 63: 2396-8
14. Mastaglia FL, Needham M, Scott A, James I, Zilko P, Day T, Kiers L, Corbett A, Witt CS, Allcock R, Laing N, Garlepp M, Christiansen FT. Sporadic inclusion body myositis: HLA DRB1 allele interactions influence disease risk and clinical phenotype. Neuromuscul Disord 2009; 19: 763-5
15. Sivakumar K, Semino-Mora C, Dalakas MC. An inflammatory, familial, inclusion body myositis with autoimmune features and a phenotype identical to sporadic inclusion body myositis: studies in 3 families. Brain 1997; 120: 653-61
16. Griggs RC, Askanas V, DiMauro S, Engel A, Karpati G, Mendell JR, Rowland LP. Inclusion body myositis and myopathies. Ann Neurol 1995; 38: 705-13
17. Karpati G, Carpenter S. Pathology of the inflammatory myopathies. Baillieres Clin Neurol 1993; 2: 527-56
18. Needham M, Fabian V, Knezevic W, Panegyres P, Zilko P, Mastaglia FL. Progressive myopathy with upregulation of MHC-I associated with statin therapy. Neuromuscul Disord 2007; 17: 194-200
19. Askanas V, Engel WK, Alvarez RB. Enhanced detection of Congo-red-positive amyloid deposits in muscle fibers of inclusion body myositis and brain of Alzheimer disease using fluorescence technique. Neurology 1993; 43: 1265-7
20. Askanas V, Engel WK, Alvarez RB, Glenner GG. b-Amyloid protein immunoreactivity in muscle of patients with inclusion-body myositis. Lancet 1992; 339: 560-1
21. Askanas V, Engel WK, Nogalska A. Inclusion body myositis: a degenerative muscle disease associated with intra-muscle fiber multi-protein aggregates, proteasome inhibition, endoplasmic reticulum stress and decreased lysosomal degradation. Brain Pathol 2009; 19: 493-506
22. Nogalska A, Terracciano C, D'Agostino C, King Engel W, Askanas V. p62/SQSTM1 is overexpressed and prominently accumulated in inclusions of sporadic inclusion-body myositis muscle fibers, and can help differentiating it from polymyositis and dermatomyositis. Acta Neuropathol 2009; 118: 407-13
23. De Bleecker JL, Ertl BB, Engel AG. Patterns of abnormal protein expression in target formations and unstructured cores. Neuromuscul Disord 1996; 6: 339-49
24. Fidzianska A, Rowinska-Marcinska K, Hausmanowa-Petrusewicz I. Coexistence of X-linked recessive Emery-Dreifuss muscular dystrophy with inclusion body myositis-like morphology. Acta Neuropathol 2004; 104: 197-203
25. Selcen D, Ohno K, Engel AG. Myofibrillar myopathy: clinical, morphological and genetic studies in 63 patients. Brain 2004; 127: 439-51
26. Ferrer I, Martin B, Castano JG, Lucas JJ, Moreno D, Olive M. Proteasomal expression, induction of immunoproteasome subunits, and local MHC class I presentation in myofibrillar myopathy and inclusion body myositis. J Neuropathol Exp Neurol 2004; 63: 484-98
27. Ferrer I, Carmona M, Blanco R. Involvement of clusterin and the aggresome in abnormal protein deposits in myofibrillar myopathies and Inclusion Body Myositis. Brain Pathol 2005; 15: 101-8
28. Semino-Mora C, Dalakas MC. Rimmed vacuoles with b-amyloid and ubiquitinated filamentous deposits in the muscles of patients with long-standing denervation (post-poliomyelitis muscular atrophy): similarities with inclusion body myositis. Hum Pathol 1998; 29: 1128-33
29. Weihl CC, Temiz P, Miller SE, Watts G, Smith C, Forman M, Hanson PI, Kimonis V, Pestronk A. TDP-43 accumulation in inclusion body myopathy muscle suggests a common pathogenic mechanism with frontotemporal dementia. J Neurol Neurosurg Psychiatry 2008; 79: 1186-9
30. Salajegheh M, Pinkus JL, Nazareno R, Amato AA, Parker KC, Greenberg SA. Nature of 'Tau' immunoreactivity in normal myonuclei and inclusion body myositis. Muscle Nerve 2009; 40: 520-8
31. Salajegheh M, Pinkus JL, Taylor JP, Amato AA, Nazareno R, Baloh RH, Greenberg SA. Sarcoplasmic redistribution of nuclear TDP-43 in inclusion body myositis. Muscle Nerve 2009; 40: 19-31
32. Chahin N, Engel AG. Correlation of muscle biopsy, clinical course, and outcome in PM and sporadic IBM. Neurology 2008; 70: 418-24
33. Goldfarb LG, Dalakas MC. Tragedy in a heartbeat: malfunctioning desmin causes skeletal and cardiac muscle disease. J Clin Invest 2009; 119: 1806-13
34. Eisenberg I, Avidan N, Potikha T, Hochner H, Chen M, Olender T, Barash M, Shemesh M, Sadeh M, Grabov-Nardini G, Shmilevich I, Friedmann A, Karpati G, Bradley WG, Baumbach L, Lancet D, Asher EB, Beckmann JS, Argov Z, Mitrani-Rosenbaum S. The UDP-N-acetylglucosamine 2-epimerase/N-acetylmannosamine kinase gene is mutated in recessive hereditary inclusion body myopathy. Nat Genet 2001; 29: 83-7
35. Dalakas MC. Mechanisms of disease: signaling pathways and immunobiology of inflammatory myopathies. Nat Clin Pract Rheumatol 2006; 2: 219-27
36. Karpati G, Pouliot Y, Carpenter S. Expression of immunoreactive major histocompatability complex products in human skeletal muscles. Ann Neurol 1988; 23: 64-72
37. Emslie-Smith AM, Arahata K, Engel AG. Major histocompatibility complex class I antigen expression, immunologicalization of interferon subtypes, and T cell-mediated cytotoxicity in myopathies. Hum Pathol 1989; 20: 224-31
38. Krahn M, Lopez de Munain A, Streichenberger N, Bernard R, Pécheux C, Testard H, Pena-Segura JL, Yoldi E, Cabello A, Romero NB, Poza JJ, Bouillot-Eimer S, Ferrer X, Goicoechea M, Garcia-Bragado F, Leturcq F, Urtizberea JA, Lévy N. CAPN3 mutations in patients with idiopathic eosinophilic myositis. Ann Neurol 2006; 59: 905-11
39. Kissel JT, Mendell JR, Rammohan KW. Microvascular deposition of complement membrane attack complex in dermatomyositis. N Engl J Med 1986; 314: 329
40. Emslie-Smith AM, Engel AG. Microvascular changes in early and advanced dermatomyositis: a quantitative study. Ann Neurol 1990; 27: 343-56
41. Basta M, Dalakas MC. High-dose intravenous immunoglobulin exerts its beneficial effect in patients with dermatomyositis by blocking endomysial deposition of activated complement fragments. J Clin Invest 1994; 94: 1729-35
42. Dalakas MC. Immunopathogenesis of inflammatory myopathies. Ann Neurol 1995; 37: 74-86
43. Stein DP, Dalakas MC. Intercellular adhesion molecule-1 expression is upregulated in patients with dermatomyositis (DM). Ann Neurol 1993; 34: 268
44. Lundberg I, Brengman JM, Engel AG. Analysis of cytokine expression in muscle in inflammatory myopathies, Duchenne's dystrophy and non-weak controls. J Neuroimmunol 1995; 63: 9-16
45. Tews DS, Goebel HH. Cytokine expression profiles in idiopathic inflammatory myopathies. J Neuropathol Exp Neurol 1996; 55: 342-7
46. Confalonieri P, Bernasconi P, Megna P, Galbiati S, Cornelio F, Mantegazza R. Increased expression of beta-chemokines in muscle of patients with inflammatory myopathies. J Neuropathol Exp Neurol 2000; 59: 164-9
47. De Bleecker JL, De Paepe B, Vanwalleghem IE, Schröder JM. Differential expression of chemokines in inflammatory myopathies. Neurology 2002; 58: 1779-85
48. Figarella-Branger D, Civate M, Bartoli C, Pellissier JF. Cytokines, chemokines, and cell adhesion molecules in inflammatory myopathies. Muscle Nerve 2003; 28: 659-82
49. Mammen AL, Casciola-Rosen LA, Hall JC, Christopher-Stine L, Corse AM, Rosen A. Expression of the dermatomyositis autoantigen Mi-2 in regenerating muscle. Arthritis Rheum 2009; 60: 3784-93
50. Gallardo E, de Andrés I, Illa I.. Cathepsins are upregulated by IFN-gamma/STAT1 in human muscle culture: a possible active factor in dermatomyositis. J Neuropathol Exp Neurol 2001; 60: 847-55
51. Greenberg SA, Pinkus JL, Pinkus GS, Burleson T, Sanoudou D, Tawil R, Barohn RJ, Saperstein DS, Briemberg HR, Ericsson M, Park P, Amato AA. Interferon-alpha/beta-mediated innate immune mechanisms in dermatomyositis. Ann Neurol 2005; 57: 664-78
52. Walsh RJ, Kong SW, Yao Y, Jallal B, Kiener PA, Pinkus JL, Beggs AH, Amato AA, Greenberg SA. Type I interferon-inducible gene expression in blood is present and reflects disease activity in dermatomyositis and polymyositis. Arthritis Rheum 2007; 56: 3784-92
53. Tezak Z, Hoffman EP, Lutz JL, Fedczyna TO, Stephan D, Bremer EG, Krasnoselska-Riz I, Kumar A, Pachman LM. Gene expression profiling in DQA1*0501+ children with untreated dermatomyositis: a novel model of pathogenesis. J Immunol 2002; 168: 4154-63
54. Raju R, Dalakas MC. Gene expression profile in the muscles of patients with inflammatory myopathies: effect of therapy with IVIg and biological validation of clinically relevant genes. Brain 2005; 128: 1887-96
55. Amemiya K, Semino-Mora C, Granger RP, Dalakas MC. Downregulation of TGF-β1 mRNA and protein in the muscles of patients with inflammatory myopathies after treatment with high-dose intravenous immunoglobulin. Clin Immunol 2000; 94: 99-104
56. Leff RL, Love LA, Miller FW, Greenberg SJ, Klein EA, Dalakas MC, Plotz PH. Viruses in the idiopathic inflammatory myopathies: absence of candidate viral genomes in muscle. Lancet 1992; 339: 1192-5
57. Leon-Monzon M, Dalakas MC. Absence of persistent infection with enteroviruses in muscles of patients with inflammatory myopathies. Ann Neurol 1992; 32: 219-22
58. Arahata K, Engel AG. Monoclonal antibody analysis of mononuclear cells in myopathies. I: quantitation of subsets according to diagnosis and sites of accumulation and demonstration and counts of muscle fibres invaded by T cells. Ann Neurol 1984; 16: 193-208
59. Arahata K, Engel AG. Monoclonal antibody analysis of mononuclear cells in myopathies. IV: cell-mediated cytotoxicity and muscle fiber necrosis. Ann Neurol 1988; 23: 168-73
60. Engel AG, Arahata K. Monoclonal antibody analysis of mononuclear cells in myopathies. II: phenotypes of autoinvasive cells in polymyositis and inclusion body myositis. Ann Neurol 1984; 16: 209-15
61. Engel AG, Arahata K. Mononuclear cells in myopathies: quantitation of functionally distinct subsets, recognition of antigen-specific cell-mediated cytotoxicity in some diseases, and implications for the pathogenesis of the different inflammatory myopathies. Hum Pathol 1986; 17: 702-21
62. Hohlfeld R, Engel AG. The immunobiology of muscle. Immunol Today 1994; 15: 269-74
63. Wiendl H, Hohlfeld R, Kieseier BC. Immunobiology of muscle: advances in understanding an immunological microenvironment. Trends Immunol 2005; 26: 373-80
64. Wiendl H, Mitsdoerffer M, Schneider D, Melms A, Lochmuller H, Hohlfeld R, Weller M. Muscle fibres and cultured muscle cells express the B7.1/2-related inducible co-stimulatory molecule, ICOSL: implications for the pathogenesis of inflammatory myopathies. Brain 2003; 126: 1026-35
65. Schmidt J, Rakocevic G, Raju R, Dalakas MC. Upregulated inducible co-stimulator (ICOS) and ICOS-ligand in inclusion body myositis muscle: significance for CD8+ T cell cytotoxicity. Brain 2004; 127: 1182-90
66. Pruitt JN 2nd, Showalter CJ, Engel AG. Sporadic inclusion body myositis: counts of different types of abnormal fibers. Ann Neurol 1996; 39: 139-43
67. Confalonieri P, Oliva L, Andreetta F, Lorenzoni R, Dassi P, Mariani E, Morandi L, Mora M, Cornelio F, Mantegazza R. Muscle inflammation and MHC class I up-regulation in muscular dystrophy with lack of dysferlin: an immunopathological study. J Neuroimmunol 2003; 142: 130-6
68. Goebels N, Michaelis D, Engelhardt M, Huber S, Bender A, Pongratz D, Johnson MA, Wekerle H, Tschopp J, Jenne D, Hohlfeld R. Differential expression of perforin in muscle-infiltrating T cell in polymyositis and dermatomyositis. J Clin Invest 1996; 97: 2905
69. Hohlfeld R, Engel AG. Coculture with autologous myotubes of cytotoxic T cells isolated from muscle in inflammatory myopathies. Ann Neurol 1991; 29: 498-507
70. Behrens L, Bender A, Johnson MA, Hohlfeld R. Cytotoxic mechanisms in inflammatory myopathies: co-expression of Fas and protective Bcl-2 in muscle fibres and inflammatory cells. Brain 1997; 120: 929
71. Schneider C, Gold R, Dalakas MC, Schmied M, Lassmann H, Toyka KV, Hartung HP. MHC class I mediated cytotoxicity does not induce apoptosis in muscle fibers nor in inflammatory T cells: studies in patients with polymyositis, dermatomyositis, and inclusion body myositis. J Neuropath Exp Neurol 1996; 55: 1205-9
72. Mantegazza R, Hughes SM, Mitchell D, Travis M, Blau HM, Steinman L. Modulation of MHC class II antigen expression in human myoblasts after treatment with IFN-gamma. Neurology 1991; 41: 1128
73. Bao SS, King NJ, dos Remedios CG. Elevated MHC class I and II antigens in cultured human embryonic myoblasts following stimulation with gamma-interferon. Immunol Cell Biol 1990; 68: 235-41
74. Hohlfeld R, Engel AG. Induction of HLA-DR expression on human myoblasts with interferon-gamma. Am J Pathol 1990; 136: 503
75. Roy R, Dansereau G, Tremblay JP, Belles-Isles M, Huard J, Labrecque C, Bouchard JP. Expression of major histocompatibility complex antigens on human myoblasts. Transplant Proc 1991; 23: 799
76. De Bleecker JL, Meire VI, Declercq W, Van Aken HE. Immunolocalization of tumor necrosis factor-alpha and its receptors in inflammatory myopathies. Neuromusc Disord 1999; 9: 239
77. Raju R, Vasconcelos O, Granger R, Dalakas MC. Expression of IFN-gamma-inducible chemokines in inclusion body myositis. J Neuroimmunol 2003; 141: 125-31
78. Bender A, Ernst N, Iglesias A, Dornmair K, Wekerle H, Hohlfeld R. T cell receptor in polymyositis: clonal expansion of autoaggressive CD81 T cells. J Exp Med 1995; 181: 1863-8
79. Mantegazza R, Andreetta F, Bernasconi P, Baggi F, Oksenberg JR, Simoncini O, Mora M, Cornelio F, Steinman L. Analysis of T cell receptor repertoire of muscle infiltrating T lymphocytes in polymyositis. J Clin Invest 1993; 91: 2880-6
80. O'Hanlon TP, Dalakas MC, Plotz PH, Miller FW. Predominant TCR-alpha-beta variable and joining gene expression by muscle-infiltrating lymphocytes in the idiopathic inflammatory myopathies. J Immunol 1994; 152: 2569-76
81. Benveniste O, Herson S, Salomon B, Dimitri D, Trébeden-Nègre H, Jean L, Bon-Durand V, Antonelli D, Klatzmann D, Boyer O. Long-term persistence of clonally expanded T cells in patients with polymyositis. Ann Neurol 2004; 56: 867-72
82. Fyhr IM, Moslemi AR, Mosavi AA, Lindberg C, Tarkowski A, Oldfors A. Oligoclonal expansion of muscle infiltrating T cells in inclusion body myositis. J Neuroimmunol 1997; 79: 185-9
83. Bender A, Behrens L, Engel AG, Hohlfeld R. T-cell heterogeneity in muscle lesions of inclusion body myositis. J Neuroimmunol 1998; 84: 86-91
84. Nishio J, Suzuki M, Miyasaka N, Kohsaka H. Clonal biases of peripheral CD8 T cell repertoire directly reflect local inflammation in polymyositis. J Immunol 2001; 167: 4051-8
85. Amemiya K, Granger RP, Dalakas MC. Clonal restriction of T-cell receptor expression by infiltrating lymphocytes in inclusion body myositis persists over time. Studies in repeated muscle biopsies. Brain 2000; 123: 2030-9
86. Hofbauer M, Wiesener S, Babbe H, Roers A, Wekerle H, Dornmair K, Hohlfeld R, Goebels N. Clonal tracking of autoaggressive T cells in polymyositis by combining laser microdissection, single-cell PCR, and CDR3-spectratype analysis. Proc Natl Acad Sci USA 2003; 100: 4090-5
87. Hohlfeld R, Engel AG, Kunio LI, Harper MC. Polymyositis mediated by T lymphocytes that express the gamma/delta receptor. N Engl J Med 1991; 324: 877-81
88. Puschke G, Ruegg D, Hohlfeld R, Engel AG. Autoaggressive myocytotoxic T-lymphocytes expressing an unusual gamma delta T cell receptor. J Exp Med 1992; 176: 1785-9
89. Wiendl H, Malotka J, Holzwarth B, Weltzien HU, Wekerle H, Hohlfeld R, Dornmair K. An autoreactive gamma delta TCR derived from a polymyositis lesion. J Immunol 2002; 169: 515-21
90. Murata K, Dalakas MC. Expression of the costimulatory molecule BB-1, the ligands CTLA-4 and CD28 and their mRNA in inflammatory myopathies. Am J Pathol 1999; 155: 453-60
91. Schmidt J, Barthel K, Wrede A, Salajegheh M, Bähr M, Dalakas MC. Interrelation of inflammation and APP in sIBM: IL-1 beta induces accumulation of beta-amyloid in skeletal muscle. Brain 2008; 131: 1228-4050
92. Choi YC, Dalakas MC. Expression of matrix metalloproteinases in the muscle of patients with inflammatory myopathies. Neurology 2000; 54: 65-71
93. De Bleecker JL, Engel AG. Expression of cell adhesion molecules in inflammatory myopathies and Duchenne dystrophy. J Neuropathol Exp Neurol 1994; 53: 369-76
94. Greenberg SA, Pinkus GS, Amato AA, Pinkus JL. Myeloid dendritic cells in inclusion-body myositis and polymyositis. Muscle Nerve 2007; 35: 17-23
95. Bradshaw EM, Orihuela A, McArdel SL, Salajegheh M, Amato AA, Hafler DA, Greenberg SA, O'Connor KC. A local antigen-driven humoral response is present in the inflammatory myopathies. J Immunol 2007; 178: 547-56
96. Chou SM. Inclusion body myositis: a possible chronic persistent mumps myositis? Hum Pathol 1986; 17: 765-76
97. Dalakas MC. Inflammatory, immune, and viral aspects of inclusion-body myositis. Neurology 2006; 66: 33-8
98. Nishino H, Engel AG, Rima BK. Inclusion body myositis: the mumps virus hypothesis. Ann Neurol 1989; 25: 260-4
99. Dalakas MC, London WT, Gravell M, Sever JL. Polymyositis in an immunodeficiency disease in monkeys induced by a type D retrovirus. Neurology 1986; 36: 569-72
100. Dalakas MC, Pezeshkpour GH, Gravell M, Sever JL. Polymyositis in patients with AIDS. JAMA 1986; 256: 2381-3
101. Dalakas MC, Pezeshkpour GH. Neuromuscular diseases associated with human immunodeficiency virus infection. Ann Neurol 1989; 23 (Suppl.): 38-48
102. Morgan OSC, Rodgers-Johnson P, Mora C, Char G. HTLV-1 and polymyositis in Jamaica. Lancet 1989; 2: 1184-7
103. Illa I, Nath A, Dalakas MC. Immunocytochemical and virological characteristics of HIV-associated inflammatory myopathies: similarities with seronegative polymyositis. Ann Neurol 1991; 29: 474-81
104. Leon-Monzon M, Dalakas MC. Interleukin-1 (IL-1) is toxic to human muscle. Neurology 1994; 44: 132
105. Leon-Monzon M, Lamperth L, Dalakas MC. Search for HIV proviral DNA and amplified sequences in the muscle biopsies of patients with HIV-polymyositis. Muscle Nerve 1993; 16: 408-13
106. Cupler EJ, Leon-Monzon M, Miller J, Semino-Mora C, Anderson TL, Dalakas MC. Inclusion body myositis in HIV-I and HTLV-I infected patients. Brain 1996; 19: 1887-93
107. Saito M, Higuchi I, Saito A, Izumo S, Usuku K, Bangham CR, Osame M. Molecular analysis of T cell clonotypes in muscle-infiltrating lymphocytes from patients with human T lymphotropic virus type 1 polymyositis. J Infect Dis 2002; 186: 1231-41
108. Ozden S, Cochet M, Mikol J, Teixeira A, Gessain A, Pique C. Direct evidence for a chronic CD8+-T-cell-mediated immune reaction to tax within the muscle of a human T-cell leukemia/lymphoma virus type 1-infected patient with sporadic inclusion body myositis. J Virol 2004; 78: 10320-7
109. Dalakas MC, Rakocevic G, Shatunov A, Goldfarb L, Salajegheh M. IBM with HIV infection: 4 new cases withclonal expansion of viral-specific T cells. Ann Neurology 2007; 61: 466-75
110. Fratta P, Engel WK, McFerrin J, Davies KJ, Lin SW, Askanas V. Proteasome inhibition and aggresome formation in sporadic inclusion-body myositis and in amyloid-beta precursor protein-overexpressing cultured human muscle fibers. Am J Pathol 2005; 167: 517-26
111. Vattemi G, Engel WK, McFerrin J, Buxbaum JD, Pastorino L, Askanas V. Presence of BACE1 and BACE2 in muscle fibres of patients with sporadic inclusion-body myositis. Lancet 2001; 358: 1962-4
112. Lünemann JD, Schmidt J, Schmid D, Barthel K, Wrede A, Dalakas MC, Münz C. Beta-amyloid is a substrate of autophagy in sporadic inclusion body myositis. Ann Neurol 2007; 61: 476-83
113. Schmid D, Münz C. Localization and MHC class II presentation of antigens targeted for macroautophagy. Methods Mol Biol 2008; 445: 213-25
114. Dalakas MC. Molecular immunology and genetics of inflammatory muscle diseases. Arch Neurol 1998; 55: 1509-12
115. Dalakas MC. Molecular links between inflamation and degeneration: lessons on 'Neuroinflammation' using IBM as a model. Ann Neurology 2008; 64: 1-3
116. Kitazawa M, Trinh DN, LaFerla FM. Inflammation induces tau pathology in inclusion body myositis model via glycogen synthase kinase-3beta. Ann Neurol 2008; 64: 15-24
117. Banwell BL, Engel AG. AlphaB-crystallin immunolocalization yields new insights into inclusion body myositis. Neurology 2000; 54: 1020-1
118. Muth IE, Barthel K, Bähr M, Dalakas MC, Schmidt J. Proinflammatory cell stress in sporadic inclusion body myositis muscle: overexpression of alphaB-crystallin is associated with amyloid precursor protein and accumulation of beta-amyloid. J Neurol Neurosurg Psychiatry 2009; 80: 1344-9
119. Miller T, Al-Lozi MT, Lopate G, Pestronk A. Myopathy with antibodies to the signal recognition particle: clinical and pathological features. J Neurol Neurosurg Psychiatry 2002; 73: 420-8
120. Christofer-Stine L, Casciola-Rosen LA, Hong G, Chung T, Corse AM, Mammen AL. A novel autoantibody recognizing 200 and 100 kDa proteins is associated with an immune-mediated necrotizing myopathy. Arthr Rheum 2010; 62: 2757-66
121. Hengstman GJ, van Engelen BG, van Venrooij WJ. Myositis specific autoantibodies: changing insights in pathophysiology and clinical associations. Curr Opin Rheumatol 2004; 16: 692-9
122. Dalakas MC. Toxic and drug-induced myopathies. J Neurol Neurosurg Psychiatry 2009; 80: 832-8
123. Dalakas MC. Therapeutic targets in patients with inflammatory myopathies: present approaches and a look to the future. Neuromuscular Disord 2006; 16: 223-36
124. Dalakas MC. Immunotherapy of myositis: issues, concerns and future prospects. Nat Rev Rheumatol 2010; 6: 129-37
125. Mastalgia FL, Garlepp MJ, Phillips BA, Zilko PJ. Inflammatory Myopathies: clinical, diagnostic and therapeutic aspects. Muscle Nerve 2003; 27: 407-25
126. Needham M, Mastaglia FL. Sporadic inclusion body myositis: a continuing puzzle. Neuromuscul Disord 2008; 18: 6-16
127. Dalakas MC, Sekul EA, Cupler EJ, Sivakumar K. The Efficacy of High Dose Intravenous Immunoglobulin (IVIg) in Patients With Inclusion-Body Myositis (IBM). Neurology 1997; 48: 712-16
128. Layzer R, Lee HS, Iverson D, Margeta M. Dermatomyositis with inclusion body myositis pathology. Muscle Nerve 2009; 40: 469-71
129. Dalakas MC, Rakocevic G, Schmidt J, Salajegheh M, McElroy B, Harris-Love MO, Shrader JA, Levy EW, Dambrosia J, Kampen RL, Bruno DA, Kirk AD. Effect of Alemtuzumab (CAMPATH 1-H) in patients with inclusion-body myositis. Brain 2009; 132: 1536-44
130. Hughes RA, Dalakas MC, Cornblath DR, Latov N, Weksler ME, Relkin N. Clinical applications of intravenous immunoglobulins in neurology. Clin Exp Immunol 2009; 158 (Suppl. 1): 34-42